SCYNEXIS Inc (SCYX)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$5.30-0.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
SCYNEXIS is integrating Poxel's research assets to expand its drug pipeline. It targets up to $146 million in sales milestones for BREXAFEMME. The company secured funding to support operations into mid-2029. These steps could stabilize and grow revenue from a low base.
Revenue is expected to decline about 53% next year. The company is loss-making and faces elevated risk. Funding and integration challenges could delay growth and worsen losses.
The market expects about a 53% revenue decline next year, reflecting skepticism on growth. Our fair value at $18.3 suggests some recovery potential, but risks remain high.
Breaks if: sales milestones fall significantly short of $146 million by 2029
SCYNEXIS targets up to $146M in sales milestones for BREXAFEMME.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making, and while it has some positive recent developments, the overall risk is high due to potential earnings misses and market conditions.
The market appears to be pricing in a moderate expectations gap, suggesting that investors are not fully convinced of SCYX's growth potential. The valuation is aligned with peers, but SCYX trades at a slight premium, indicating some optimism about its future.
Management is focused on achieving sales milestones and completing an acquisition, which could improve fundamentals. However, there is a high probability of an earnings miss in the near term, which adds to the uncertainty.
The thesis hinges on several factors, including the company's ability to meet guidance, the performance of the broader healthcare sector, and macroeconomic conditions affecting job growth. Positive signals from sector peers could provide a favorable environment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: funding falls short of sustaining operations through mid-2029
SCYNEXIS plans to use proceeds from a private placement to fund operations into mid-2029.
Breaks if: integration progress stalls or reverses within next 12 months
SCYNEXIS aims to integrate Poxel's AMP kinase activator research and development program assets.
Over the next 1 to 3 years, SCYX's prospects will depend heavily on execution and external market factors. Not investment advice.